SCOTUS Decision in Google v. Oracle: Distorting ‘Fair Use’ but the Scathing (and Logical) Dissent is the One Saving Grace (Part I)

by Adarsh Ramanujan April 7, 2021

On 5th April, the Supreme Court of the United States allowed Google’s appeal and held that Google’s copying of roughly 11,500 lines of code relating to 37 software packages forming part of Sun Java Application Programming Interface (API), owned by Oracle, was protected by ‘fair use’. The majority opinion was delivered by Justice Breyer (joined by 5 other judges), and a dissenting opinion was filed by Justice Thomas (joined by one other judge). One judge (Justice Barrett took no part…

Patent

Madras High Court Grants Interim Injunction to Kibow Biotech, Making Problematic Observations on Patentability of Subject Matter

by Praharsh Gour April 5, 2021

Leave a Comment

Recently Madras High Court added another tale in the litigation scrimmage between US corporate Kibow Biotech and Indian entities La Renon Healthcare Pvt. Ltd. and Stanford Labs Pvt. Ltd. (not to be confused with the American university) by “making absolute” a previously granted interim injunction against the Indian entities, via its order dated 01/04/2021 (pdf). Back in 2013 we had reported about a rare occurrence in Indian IP litigation where the IPAB’s order against the revocation of a patent was…

Breaking: President Promulgates Tribunal Reforms (Rationalisation and Conditions of Service) Ordinance 2021

by Praharsh Gour April 5, 2021

1 Comment

IPAB has been in the eye of the storm since its inception. While there are ardent believers of the institution (See here and here), there are equally strong arguments by the ones against it (few of them advanced by the former Chairperson of the institution itself!) (See here here and here). A few months ago, the Executive seemingly laid the debate to rest by introducing the Tribunal Reforms (Rationalisation and Conditions of Service) Bill 2021, proposing to scrap IPAB. However,…

SpicyIP Weekly Review (March 29 – April 4)

by Anupriya Dhonchak April 5, 2021

Leave a Comment

Topical Highlight Intellectual Property Rights in Covaxin – Part 2 (IP Ownership in Publicly Funded Research) In Part II of this post, Anupriya and Swaraj analyse the broader issue of IP ownership in outcomes of publicly funded research. They note that the government’s retention of IPR in Covaxin and the novel mRNA vaccine in the pipeline, would enable it to be in a position to share them with the rest of the developing world. They examine the patchwork of rules,…

Non-Fungible Tokens (NFT) Sales and Copyright Assignment: Part II (Some Issues for Discussion)

by Adarsh Ramanujan April 5, 2021

Leave a Comment

In Part I, I briefly introduced NFTs, how they operate and why they are being hailed by content creators in the digital space. I had postulated that the NFT sale may just be the sale of the original/authentic copy of the work, or attached with a copyright license, or even an assignment, depending on the contractual terms. I had surmised that it would most likely not have any copyright license or assignment, based on a few contracts I could locate…

Non-Fungible Tokens (NFT) Sales and Copyright Assignment: Part I (The Contract is the Key)

by Adarsh Ramanujan April 5, 2021

1 Comment

(Editor’s note: If readers are unfamiliar with what Non-Fungible Tokens (NFTs) are and would like an explainer, you can refer to our earlier post by Awani Kelkar here. Adarsh’s two-part post goes on to do a deep dive including into some of the questions raised there.) NFTs have been all the rage quite recently, and many would have come across the articles on some NFTs being been sold for huge money by way of auction (here, here). But what does…

Non-Fungible Tokens (NFTs) and Copyright Law: A “Nifty” Dilemma

by SpicyIP April 5, 2021

Leave a Comment

Techno-friendly readers may have noticed that there is a sudden surge of interest in Non-Fungible Tokens (NFTs) across the internet and may have even purchased some for themselves. Some more luddite readers like myself may have still been grappling with this ‘blockchain thing’, and now find ourselves needing to know about NFTs as well! What exactly are they? Why the sudden interest in them? What implications do they have, especially on copyright law? Well, we’re pleased to bring our readers…

Copyright Rules Amendment 2021: Appellate Board, Copyright Societies, and More

by Nikhil Purohit April 2, 2021

Leave a Comment

The Central Government recently notified the Copyright (Amendment) Rules, 2021 (the ‘amendments’) on March 30, amending the Copyright Rules, 2013. Notably, around 2 years back, on May 30, 2019, a draft of these amendments was released for public comments. The amendments build upon this draft and reflect some similar changes as the draft, but at the same time they differ from the draft in several substantive aspects. In this post, I shall highlight the key implications of the 2021 amendments…

Patent

European Decision on Patentability of Simulations and Implications for India

by SpicyIP April 1, 2021

Leave a Comment

We’re pleased to bring to you a guest post by our former blogger Rajiv Choudhry, discussing a recent decision by the Enlarged Board of Appeals at the European Patent Office on patentability of simulations and its implications for Indian patent law. Rajiv is a practicing advocate based in New Delhi. He specialises in IP law, with a focus on high – technology and patent law and advises/represents clients on SEP/FRAND and other issues related or unrelated to those discussed in the…

COVID-19 Data Exclusivity Drug Regulation Innovation Patent Trade Secret

Intellectual Property Rights in Covaxin – Part 3 (IP Rights over Clinical Drug Trials (CT) Data)

by Anupriya Dhonchak March 29, 2021

Leave a Comment

In Part I of this post, Anik and I argued that the government should waive the IPR in Covaxin in order to ensure that the vaccine can be rapidly accessed by the public. In Part II of this post, Swaraj and I explored the broader issue of IP ownership in outcomes of publicly funded research. In Part III, I analyse the opacity surrounding the clinical trial data generated during the Covaxin trial, which has not been publicly shared on grounds…

Adyasha Samal { That's right, it is an ad-interim injunction. I realize that's not very clear from the post (will add an edit), but my point here is not that granting... }
Jagdish Sagar { I have noticed this interesting article a little late. Three comments: (1) there is absolutely no discussion or reference to section 3 of the Copyright Act which defines... }
Anon { "It is important to note that S&S Canada had not filed a written statement, but the interim injunction was granted nonetheless." Please note that the language of the... }
V.P { Mr. Khadher, I am currently reading a copy of this book, and have read your review and comments with interest. I think you have made some valid points,... }
Devangini Rai { Thank you! Yours was equally good. }